Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)

OSLO, Norway, Oct. 12, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the Company and its collaborators will present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Association of Nuclear Medicine (13-17 October 2018, Düsseldorf, Germany).

The presentations are:

Therapeutic efficacy of 177Lu-lilotomab satetraxetan in non-Hodgkin B-cell Lymphoma is controlled by G2/M cell cycle progression

Authors:  A. Pichard et al.
Session: 305 - M2M: Therapy Effects, Preclinical
Abstract No. OP-069
Format: Oral presentation

Date/time: Sunday 14 October, 11:30-12:45 CEST

Tumor Absorbed Dose and Changes in FDG PET Parameters in Non-Hodgkin Lymphoma Patients Treated with 177Lu-lilotomab satetraxetan

Authors: A. Løndalen et al.
Session: 608 - Clinical Oncology - Rapid Fire Session: It´s in the Blood!
Abstract No. OP-252
Format: Oral presentation

Date/time: Monday 15 October, 08:00-09:30 CEST

Abstracts are available by clicking here clicking here

For further information, please contact:

IR enquiries

Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: [email protected]

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: [email protected]

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com

This information was brought to you by Cision http://news.cision.com

http://news.cision.com/nordic-nanovector/r/nordic-nanovector-presentations-at-the-annual-congress-of-the-european-association-of-nuclear-medici,c2642692

SOURCE Nordic Nanovector

Related Links

http://www.nordicnanovector.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED